110 1151									
e at -20C	MSH6 (P150) Antibody								
Store		Orders: 877-616-CELL (2355) orders@cellsignal.com							
		Support: 877-678-TECH (8324)							
#3995		Web: info@cellsignal.com cellsignal.com							
#		3 Trask Lane Danvers Massachusetts 01923 USA							

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity: H M R Mk	Sensitivity: Endogenous	MW (kDa): 160	Source/Isotype: Rabbit	UniProt ID: #P52701	Entrez-Gene Id: 2956		
Product Usage Information		Application Western Blotting		Dilution 1:1000				
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.						
Specificity/Sensitivity		MSH6 (P150) Antibody detects endogenous levels of total MSH6 protein.						
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human MSH6. Antibodies are purified using protein A and peptide affinity chromatography.						
Background Background References		The DNA mismatch repair system (MMR) repairs post-replication DNA, inhibits recombination between nonidentical DNA sequences, and induces both checkpoint and apoptotic responses following certain types of DNA damage (1). MSH2 (MutS homologue 2) forms the hMutS- α dimer with MSH6 and is an essential component of the mismatch repair process. hMutS- α is part of the BRCA1-associated surveillance complex (BASC), a complex that also contains BRCA1, MLH1, ATM, BLM, PMS2 proteins, and the Rad50-Mre11-NBS1 complex (2). Mutations in MSH6 and other MMR proteins have been found in a large proportion of hereditary nonpolyposis colorectal cancer (Lynch Syndrome), the most common form of inherited colorectal cancer in the Western world (3). Mutations in MSH6 have been shown to occur in glioblastoma in response to temozolomide therapy and to promote temozolomide resistance (4).						
		1. O'Brien, V. and Brown, R. (2006) <i>Carcinogenesis</i> 27, 682-92. 2. Wang, Y. et al. (2000) <i>Genes Dev</i> 14, 927-39. 3. Plotz, G. et al. (2006) <i>J Mol Histol</i> 37, 271-83. 4. Yip, S. et al. (2009) <i>Clin Cancer Res</i> 15, 4622-9.						
Species Reactiv	ity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).						
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.						
Applications Key		W: Western Blotting						
Cross-Reactivity Key		H: Human M: Mouse R: Rat Mk: Monkey						
Trademarks and	d Patents	Cell Signaling Technol	ogy is a trademark	of Cell Signaling Techno	logy, Inc.			
		All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.						
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.						
		approved, cleared, or purpose. Customer sh any manner that confl	licensed by the FDA all not use any Pro licts with its labelin	lse Only or a similar labe A or other regulatory for duct for any diagnostic o g statement. Products so research and developme	eign or domestic er or therapeutic purp old or licensed by C	ntity, for any ose, or otherwise in ST are provided for		

diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.